- TherapeuticsMD ( NASDAQ: TXMD ) appointed Brian Bernick and Mark Glickman as interim co-CEO and co-principal executive officers.
- Bernick and Glickman succeed Hugh O’Dowd as CEO, the company said in a Sept. 12 press release.
- Prior to this appointment, Bernick, the company's co-founder, served as chief scientific and medical officer, and Glickman served as chief business officer.
- TherapeuticsMD also appointed Tommy Thompson, who served as chairman since 2012, as the executive chairman of the Board.
For further details see:
TherapeuticsMD appoints interim co-CEOs